Skip to content

Roivant Sciences ROIV Price / earnings

Price / earnings at other companies

Amgen logo
AmgenAMGN
24.3×-3.9×
Moderna logo
ModernaMRNA
38.4×+34.3×
Royalty Pharma logo
Royalty PharmaRPRX
24.8×+12.5×
ALN
Alnylam PharmaceuticalsALNY
87.4×
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
19.8×-16.3×
Incyte logo
IncyteINCY
13.1×-538×

Other financials

Income statement

See full
Revenue$2.5M-66.7%

Balance sheet

See full
Cash & equivalents$1.4B+1,411%
Total debt$107.4M+7.3%
Total equity$4.5B-3.4%
Total assets$5.7B+5.0%

Cash flow

See full
Operating cash flow-$163.8M+5.1%
CapEx$1.3M+55.5%
Free cash flow-$165.1M+4.8%

Valuation

See full
Market cap$22.44B+175%
Enterprise value$21.13B+157%
P/S2,716.9×+2,436×

Profitability

See full
Operating margin-9,130.5%-13,995pp
Net margin-6,079.9%-6,193pp

Returns & leverage

See full
Return on equity-17.1%-17.7pp
Debt / equity0.0×
Current ratio18.4×-15.1×

Where this comes from

Calculated from Roivant Sciences’s reported figures.

Based on the most recent quarter.

The official record: Roivant Sciences’s 10-Q, filed February 10, 2025, on SEC EDGAR. View the filing →

Ask your AI about Roivant Sciences's price / earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Roivant Sciences's price / earnings?
Roivant Sciences (ROIV) reported price / earnings of 249.7× in Q4 2024.
How has Roivant Sciences's price / earnings changed year-over-year?
Roivant Sciences's price / earnings increased by 12302.8% year-over-year, from 2× to 249.7×.
What does price / earnings mean?
How many dollars investors pay for each dollar of the company's annual profit.
How do you interpret price / earnings?
Lower can mean cheaper — or that the market expects earnings to fall. High multiples embed growth expectations. Meaningless when earnings are negative, so it is suppressed there.
How does price / earnings compare across companies?
Compare against the company's own history and sector peers, not across sectors with different growth and risk profiles.